leadf
logo-loader
viewChimeric Therapeutics Ltd
(
ASX:CHM
)

Chimeric Therapeutics with Proactive at the ASX Small and Mid Cap Conference

Chimeric Therapeutics Ltd (ASX:CHM)'s Jennifer Chow speaks to Proactive's Andrew Scott from the ASX Small and Mid Cap Conference - September 2021. Chimeric is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. Its lead program is CHM 1101, a novel CAR T therapy, for the treatment of patients with Glioblastoma.

Quick facts: Chimeric Therapeutics Ltd

Follow
ASX:CHM

Price: 0.335 AUD

Market Cap: $111.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Tony Locantro says Mako Gold well cashed-up and delivering consistent results

Alto Capital's Tony Locantro touches on Mako Gold Ltd (ASX:MKG)'s quarterly report which was out this morning as well as recent news from Alta Zinc Ltd (ASX:AZI) which has received funding support for an innovative remote sensing and laser project through the EIT Raw Materials program at its...

on 29/7/21

2 min read